NEW YORK ( TheStreet) --This feels like deja vu all over again, as Yogi Berra famously phrased it. In the past few years whenever a successful company spins off a division it frequently leads to two chances to "buy low and sell high."As you may have heard, Abbott Laboratories (ABT - Get Report) completed its promised spin-off of AbbVie (ABBV), which is a drug maker built largely around a drug called Humira, a best-selling rheumatoid arthritis injection that produced $7.93 billion in revenue during 2011.
The Many Reasons to Still Own Abbott Labs
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.